Clinical Trials: Regulatory Audit Findings

Data Integrity Violations: Top Regulatory Audit Findings in Clinical Trials

Posted on digi By digi

Data integrity underpins the reliability of clinical trial results. Regulatory agencies including the FDA, EMA, and MHRA emphasize that all trial data must be attributable, legible, contemporaneous, original, and accurate (the ALCOA+ principles). Any violation of these principles—such as missing audit trails, unauthorized data changes, or discrepancies between Case Report Forms (CRFs) and source data—can trigger major or critical audit findings.

Click to read the full article.

Data Integrity & EDC Audit Findings, Regulatory Audit Findings

Most Frequent Investigator Site Audit Findings in Clinical Trials

Posted on digi By digi

Investigator sites form the foundation of clinical trials. Regardless of sponsor oversight or CRO involvement, the quality of trial conduct at each site determines the overall credibility of a study. Regulatory authorities such as the FDA, EMA, MHRA, and PMDA conduct inspections at investigator sites to verify compliance with ICH-GCP and regional regulations. Site-level audit findings are among the most frequently reported deficiencies in inspection reports, and they can lead to delays, sanctions, or rejection of trial data.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Missing or Incomplete Informed Consent Forms: A Top Audit Finding

Posted on digi By digi

Informed consent is the ethical and regulatory cornerstone of clinical trial conduct. It ensures that participants are fully aware of the trial’s purpose, procedures, potential risks, and their right to withdraw at any time. Regulatory authorities such as the FDA, EMA, MHRA, and PMDA consistently rank missing or incomplete informed consent documentation among the top audit findings during site inspections.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Missing Audit Trails in Electronic Data Capture Systems

Posted on digi By digi

Audit trails are essential features of Electronic Data Capture (EDC) systems, ensuring transparency, traceability, and accountability in clinical trial data. An audit trail records all data entries, changes, deletions, and user actions with timestamps, supporting compliance with ICH E6 (R2), FDA 21 CFR Part 11, and EMA GCP requirements.

Click to read the full article.

Data Integrity & EDC Audit Findings, Regulatory Audit Findings

Investigator Oversight Deficiencies in Clinical Trial Audit Reports

Posted on digi By digi

Principal Investigators (PIs) hold ultimate responsibility for the conduct of clinical trials at their sites. Regulatory agencies such as the FDA, EMA, and MHRA consistently identify inadequate investigator oversight as a major deficiency during audits and inspections. Oversight failures may include insufficient supervision of delegated tasks, lack of review of source data, or inadequate monitoring of patient safety. These deficiencies undermine compliance with ICH GCP E6(R2), jeopardize data integrity, and potentially expose trial participants to risk.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Unauthorized Data Changes Cited in Clinical Data Audit Reports

Posted on digi By digi

Clinical trial data must be reliable, verifiable, and fully traceable. Unauthorized changes to trial data—whether intentional or due to weak system controls—represent a breach of the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available). Regulatory agencies such as the FDA, EMA, and MHRA consistently identify unauthorized data changes as major or critical deficiencies during audits.

Click to read the full article.

Data Integrity & EDC Audit Findings, Regulatory Audit Findings

Delegation of Authority Log Errors: Why They Appear in Audit Findings

Posted on digi By digi

In clinical trials, the Delegation of Authority (DOA) log is a critical document that records which site staff are authorized to perform specific trial-related tasks under the supervision of the Principal Investigator (PI). Regulatory authorities such as the FDA, EMA, and MHRA often cite errors or gaps in DOA logs as frequent audit findings. These errors are not just clerical; they represent potential breaches of ICH GCP E6(R2) compliance, threatening both data integrity and patient safety.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Training Record Gaps: Common Site Audit Observations

Posted on digi By digi

In clinical trials, staff training is not optional but a fundamental requirement to ensure protocol compliance, subject safety, and data integrity. One of the most frequent site-level audit findings involves training record gaps. Regulators such as the FDA, EMA, and MHRA consistently cite missing or incomplete training documentation during inspections. These deficiencies highlight a lack of assurance that site personnel are adequately qualified to perform delegated tasks.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Discrepancies Between CRF and Source Data in Audit Observations

Posted on digi By digi

Case Report Forms (CRFs) serve as the primary medium for transferring clinical trial data from investigator sites to sponsors. Source documents—such as hospital charts, laboratory records, and diagnostic reports—provide the original clinical evidence. Regulatory agencies including the FDA, EMA, and MHRA emphasize that CRFs must accurately reflect the source data. Discrepancies between the two compromise data reliability and trigger frequent audit findings.

Click to read the full article.

Data Integrity & EDC Audit Findings, Regulatory Audit Findings

Audit Findings on Adverse Event Reporting Delays at Investigator Sites

Posted on digi By digi

Adverse event (AE) and serious adverse event (SAE) reporting is a cornerstone of subject safety in clinical trials. Regulators, including the FDA, EMA, and MHRA, consider delayed or incomplete reporting of safety events one of the most serious audit findings at investigator sites. These delays not only compromise regulatory compliance but also pose direct risks to patient safety, data reliability, and trial credibility.

Click to read the full article.

Investigator Site-Level Audit Findings, Regulatory Audit Findings